Overview of alemtuzumab therapy for the treatment of T-cell lymphomas

Pier Luigi Zinzani, Paolo Corradini, Andrea Gallamini, Alberto Grossi, Mario Lazzarino, Monia Marchetti, Maurizio Martelli, Giuseppe Rossi, Umberto Vitolo

Research output: Contribution to journalArticlepeer-review


Alemtuzumab is a humanized monoclonal antibody that recognizes the CD52 antigen expressed on malignant and normal B lymphocytes. It has come to be used therapeutically in B-cell malignancies and, in addition, it shows interesting activity also in T-cell lymphomas. Published literature and abstract proceedings were scanned, and a systematic review of phase II studies administering alemtuzumab in patients with T-cell lymphomas was performed. Alemtuzumab is an effective alternative option for patients with peripheral T-cell lymphomas and cutaneous T-cell lymphomas. Alemtuzumab may belong to the current standard of care for nodal and cutaneous T-cell lymphomas.

Original languageEnglish
Pages (from-to)789-795
Number of pages7
JournalLeukemia and Lymphoma
Issue number5
Publication statusPublished - May 2012


  • Alemtuzumab
  • cutaneous T-cell lymphomas
  • peripheral T-cell lymphomas

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Overview of alemtuzumab therapy for the treatment of T-cell lymphomas'. Together they form a unique fingerprint.

Cite this